{
    "clinical_study": {
        "@rank": "23221", 
        "arm_group": {
            "arm_group_label": "Dermal Filler - Aline HA", 
            "arm_group_type": "Experimental", 
            "description": "Single armed study"
        }, 
        "brief_summary": {
            "textblock": "The protocol hypothesis is that treatment with Aline HA\u2122 will be safe through 6 months as\n      determined by clinical assessment of treatment sites and routine tracking of adverse events."
        }, 
        "brief_title": "Safety Evaluation of Aline HA", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Correction of Wrinkles", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patient must be \u2265 21 and \u2264 70 years of age.\n\n          2. The patient must be willing and able to provide informed consent.\n\n          3. The patient must be able to read.\n\n          4. The patient is willing and able to comply with the study protocol.\n\n          5. The patient is seeking soft tissue augmentation\n\n          6. The patient has a pre-treatment Wrinkle Severity Score (WSS) \u2265 2 for any NLF to be\n             treated.\n\n          7. The patient agrees to follow-up examinations out to 6 months post final treatment.\n\n        Exclusion Criteria:\n\n          -  Exclusion Criteria: 1) The patient has had (or plans to have) cosmetic procedures to\n             treat the intended treatment area, such as:\n\n               1. Ablative or non-ablative resurfacing procedures including but not limited to\n                  medium depth or deeper chemical peeling, dermabrasion, laser resurfacing or\n                  fractional resurfacing that would affect the treatment area within the last 12\n                  months.\n\n               2. Laser or light based therapy that would affect the treatment area within the\n                  last 6 months.\n\n               3. Face, neck or brow lift or other surgical procedure of the head and neck that\n                  would affect the treatment area in the last 18 months.\n\n               4. Non-permanent dermal filler treatment in the treatment area within the last 9\n                  months.\n\n               5. Permanent implant or dermal filler treatment in the treatment area at any point\n                  in time.\n\n               6. Neurotoxin treatment that would affect the treatment area in the last 6 months,\n                  if the treatment area is below the eyes.\n\n               7. Neurotoxin treatment that would affect the treatment area in the last 9 months,\n                  if the treatment area is above the eyes.\n\n                  2) The patient has had or plans to use a pharmaceutical (topical or oral)\n                  anti-wrinkle product or other products (e.g., topical retinoids, hormone creams)\n                  affecting inflammation in the treatment area within 30 days of the study 3) The\n                  patient has inflammatory or infectious skin conditions or unhealed wounds in the\n                  treatment areas.\n\n                  4) The patient has a cancerous or pre-cancerous lesion and/or has had radiation\n                  exposure in the treatment area in the last 24 months.\n\n                  5) The patient has a history of anaphylaxis, multiple severe allergies, atopy,\n                  or is allergic to lidocaine or amide-based anesthetics, hyaluronic acid\n                  products, Streptococcal proteins or proteins from other gram positive organisms.\n\n                  6) The patient has a history of significant bleeding disorders. 7) The patient\n                  has scleroderma or fibrotic tissue disease. 8) The patient is female and of\n                  child bearing potential and/or is pregnant or lactating or is not using\n                  medically effective birth control, such as hormonal methods in use at least 30\n                  days prior to implantation, or barrier methods such as a condom and spermicide\n                  in use at least 14 days prior to implantation.\n\n                  9) The patient is using a Legally Authorized Representative. 10) The patient is\n                  an employee or employee's family member of either the Study Sponsor or a Study\n                  Site."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708213", 
            "org_study_id": "CP 10664"
        }, 
        "intervention": {
            "arm_group_label": "Dermal Filler - Aline HA", 
            "description": "Implantable dermal filler", 
            "intervention_name": "Aline HA", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "soft tissue", 
            "augmentation", 
            "correction", 
            "wrinkles"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5R3N8"
                    }, 
                    "name": "Dr. Nowell Solish"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3Z1B7"
                    }, 
                    "name": "The Westmount Institute of Plastic Surgery"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety Evaluation of Aline HA", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of this study is to assess treatment site responses and adverse events through 6 months post procedure.", 
            "measure": "Safety Evaluation of Aline HA", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary endpoints include an independent reviewer (IR) and the investigator's assessment of wrinkle severity score (WSS), if the NLF is treated, and; qualitative patient and investigator standardized questionnaires using the Global Aesthetic Improvement Scale (GAIS) if an area besides the NLF is treated.", 
            "measure": "Safety Evaluation of Aline HA", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "TauTona Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TauTona Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}